NASDAQ:TELO | Free Cash Flow | Telomir Pharmaceuticals, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$1.77M
2025-12-31-$1.2M
2025-03-31-$863,132.00
2024-12-31-$605,808.00
2024-03-31-$1.94M
2023-12-31-$1.09M
2023-03-31-$735,739.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$3.69M
2024-12-31-$5.07M
2023-12-31-$3.86M
2022-12-31-$468,661.00

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.